Jean Yoon1, Ciaran S Phibbs, Adam Chow, Hyemin Pomerantz, Martin A Weinstock. 1. *Health Economics Resource Center, Veterans Affairs Palo Alto Health Care System, Menlo Park, California; †Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA; ‡Center for Dermatoepidemiology, VA Medical Center, Providence, Rhode Island; Departments of §Dermatology, and ‖Epidemiology, Brown University, Providence, Rhode Island; ¶Department of Dermatology, Rhode Island Hospital, Providence, Rhode Island.
Abstract
BACKGROUND: The Veterans Health Administration (VHA) provides health care to large numbers of veterans afflicted with keratinocyte carcinoma (KC). OBJECTIVE: To estimate the number of veterans treated for KCs and the related diagnosis, actinic keratosis (AK) and the costs of treating these conditions over a 1-year period. MATERIALS AND METHODS: The authors conducted a cross-sectional analysis of veterans diagnosed with KC or AK during fiscal year 2012 using administrative data on outpatient encounters and prescription drugs provided or paid by VHA. Marginal costs of each condition were estimated from a regression model. The authors estimated counts of outpatient encounters, procedures, and costs related to KC and AK care. RESULTS: In 2012, there were 49,229 veterans with basal cell carcinoma, 26,310 veterans with squamous cell carcinoma, and 8,050 veterans with unspecified invasive KC. There were also 197,041 veterans with AK and 6,388 veterans with KC-related diagnoses. The VHA spent $356 million on KC and AK outpatient treatment for procedures, prescription drugs, and other dermatologic care during FY2012. CONCLUSION: There was high prevalence of KC and AK and considerable spending to treat these conditions in VHA. Treatment costs are not generalizable to care provided by non-VHA providers where a facility fee was not incurred.
BACKGROUND: The Veterans Health Administration (VHA) provides health care to large numbers of veterans afflicted with keratinocyte carcinoma (KC). OBJECTIVE: To estimate the number of veterans treated for KCs and the related diagnosis, actinic keratosis (AK) and the costs of treating these conditions over a 1-year period. MATERIALS AND METHODS: The authors conducted a cross-sectional analysis of veterans diagnosed with KC or AK during fiscal year 2012 using administrative data on outpatient encounters and prescription drugs provided or paid by VHA. Marginal costs of each condition were estimated from a regression model. The authors estimated counts of outpatient encounters, procedures, and costs related to KC and AK care. RESULTS: In 2012, there were 49,229 veterans with basal cell carcinoma, 26,310 veterans with squamous cell carcinoma, and 8,050 veterans with unspecified invasive KC. There were also 197,041 veterans with AK and 6,388 veterans with KC-related diagnoses. The VHA spent $356 million on KC and AK outpatient treatment for procedures, prescription drugs, and other dermatologic care during FY2012. CONCLUSION: There was high prevalence of KC and AK and considerable spending to treat these conditions in VHA. Treatment costs are not generalizable to care provided by non-VHA providers where a facility fee was not incurred.
Authors: Ethan Walker; Yiqiao Liu; InYoung Kim; David L Wilson; James P Basilion; Daniel L Popkin; Mark Biro; Sukanya Raj Iyer; Harib Ezaldein; Jeffrey Scott; Miesha Merati; Rachel Mistur; Bo Zhou; Brian Straight; Joshua J Yim; Matthew Bogyo; Margaret Mann Journal: Cancer Res Date: 2020-03-04 Impact factor: 12.701
Authors: Martin A Weinstock; Soe Soe Thwin; Julia A Siegel; Kimberly Marcolivio; Alexander D Means; Nicholas F Leader; Fiona M Shaw; Daniel Hogan; David Eilers; Susan M Swetter; Suephy C Chen; Sharon E Jacob; Erin M Warshaw; George P Stricklin; Robert P Dellavalle; Navjeet Sidhu-Malik; Nellie Konnikov; Victoria P Werth; Jonette E Keri; Leslie Robinson-Bostom; Robert J Ringer; Robert A Lew; Ryan Ferguson; John J DiGiovanna; Grant D Huang Journal: JAMA Dermatol Date: 2018-02-01 Impact factor: 10.282
Authors: Susan M Swetter; Julia Chang; Amanda R Shaub; Martin A Weinstock; Eleanor T Lewis; Steven M Asch Journal: JAMA Dermatol Date: 2017-08-01 Impact factor: 10.282
Authors: Howa Yeung; Marissa L Baranowski; Robert A Swerlick; Suephy C Chen; Jennifer Hemingway; Danny R Hughes; Richard Duszak Journal: JAMA Dermatol Date: 2018-11-01 Impact factor: 10.282
Authors: Pablo García-Montero; María Victoria de Gálvez-Aranda; Nuria Blázquez-Sánchez; Francisco Rivas-Ruíz; José Francisco Millán-Cayetano; Cristina García-Harana; Magdalena de Troya Martín Journal: J Cancer Educ Date: 2022-02 Impact factor: 2.037